US Stock MarketDetailed Quotes
ITOS ITeos Therapeutics
- 8.090
- +0.240+3.06%
Trading Nov 21 14:41 ET
295.56MMarket Cap-2576P/E (TTM)
8.230High7.540Low716.53KVolume7.800Open7.850Pre Close5.66MTurnover2.60%Turnover RatioLossP/E (Static)36.53MShares18.75052wk High0.47P/B222.71MFloat Cap7.54052wk Low--Dividend TTM27.53MShs Float52.430Historical High--Div YieldTTM8.79%Amplitude7.540Historical Low7.901Avg Price1Lot Size
About ITeos Therapeutics Company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Company Profile
SymbolITOS
Company NameITeos Therapeutics
Listing DateJul 24, 2020
Issue Price19.00
Founded2012
CEODr. Michel Detheux, PhD
MarketNASDAQ
Employees157
Fiscal Year Ends12-31
Address321 Arsenal Street
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-339-217-0162
Company Executives
- Name
- Position
- Salary
- Dr. Michel Detheux, PhD
- President, Chief Executive Officer and Director
- 10.51M
- Matthew Gall
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Yvonne McGrath
- Chief Scientific Officer
- --
- Matthew Call
- Chief Operating Officer
- 2.86M
- David L. Hallal
- Chairman of the Board
- 403.46K
- Dr. Robert Iannone, M.D.
- Independent Director
- 297.96K
- Jill DeSimone
- Independent Director
- --
- Tim Van Hauwermeiren, M. Sc.
- Independent Director
- 295.46K
- David K. Lee
- Independent Director
- --
- Dr. Tony Ho, M.D.
- Independent Director
- 296.96K
- Ann D. Rhoads
- Independent Director
- 309.46K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data